drugset
drugset / Trial / NCT05270668

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668 ↗

Phase 2 Active not recruiting 154 enrolled Prometheus Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.

Timeline

Start
2022-03-29
Primary completion
2026-04-16
Completion
2029-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tulisokibart Monoclonal antibody — Intravenous

Indications

diffuse cutaneous systemic sclerosis interstitial lung disease